VolitionRx (VNRX) Competitors $0.63 -0.01 (-2.17%) As of 01/17/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends VNRX vs. URGN, LFCR, ATAI, SOPH, ELDN, HRTX, CMPS, DSGN, LRMR, and FDMTShould you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include UroGen Pharma (URGN), Lifecore Biomedical (LFCR), Atai Life Sciences (ATAI), SOPHiA GENETICS (SOPH), Eledon Pharmaceuticals (ELDN), Heron Therapeutics (HRTX), COMPASS Pathways (CMPS), Design Therapeutics (DSGN), Larimar Therapeutics (LRMR), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. VolitionRx vs. UroGen Pharma Lifecore Biomedical Atai Life Sciences SOPHiA GENETICS Eledon Pharmaceuticals Heron Therapeutics COMPASS Pathways Design Therapeutics Larimar Therapeutics 4D Molecular Therapeutics UroGen Pharma (NASDAQ:URGN) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, community ranking, media sentiment and analyst recommendations. Do analysts recommend URGN or VNRX? UroGen Pharma currently has a consensus target price of $43.70, indicating a potential upside of 325.51%. VolitionRx has a consensus target price of $3.75, indicating a potential upside of 497.04%. Given VolitionRx's higher possible upside, analysts clearly believe VolitionRx is more favorable than UroGen Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score UroGen Pharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media refer more to URGN or VNRX? In the previous week, UroGen Pharma had 3 more articles in the media than VolitionRx. MarketBeat recorded 4 mentions for UroGen Pharma and 1 mentions for VolitionRx. UroGen Pharma's average media sentiment score of 0.74 beat VolitionRx's score of 0.00 indicating that UroGen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment UroGen Pharma 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VolitionRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor URGN or VNRX? UroGen Pharma received 360 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 73.94% of users gave UroGen Pharma an outperform vote while only 12.50% of users gave VolitionRx an outperform vote. CompanyUnderperformOutperformUroGen PharmaOutperform Votes36673.94% Underperform Votes12926.06% VolitionRxOutperform Votes612.50%Underperform Votes4287.50% Is URGN or VNRX more profitable? UroGen Pharma has a net margin of -129.11% compared to VolitionRx's net margin of -2,321.14%. Company Net Margins Return on Equity Return on Assets UroGen Pharma-129.11% N/A -47.94% VolitionRx -2,321.14%N/A -163.39% Do institutionals and insiders believe in URGN or VNRX? 91.3% of UroGen Pharma shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 5.1% of UroGen Pharma shares are owned by company insiders. Comparatively, 12.8% of VolitionRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better earnings & valuation, URGN or VNRX? VolitionRx has lower revenue, but higher earnings than UroGen Pharma. UroGen Pharma is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUroGen Pharma$82.71M2.91-$102.24M-$3.15-3.26VolitionRx$1.29M45.26-$35.32M-$0.36-1.74 Which has more risk & volatility, URGN or VNRX? UroGen Pharma has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. SummaryUroGen Pharma beats VolitionRx on 11 of the 18 factors compared between the two stocks. Get VolitionRx News Delivered to You Automatically Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNRX vs. The Competition Export to ExcelMetricVolitionRxDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$58.20M$2.36B$5.23B$19.35BDividend YieldN/A0.68%5.13%3.72%P/E Ratio-1.745.0687.9141.34Price / Sales45.2682.031,258.3317.06Price / CashN/A16.6543.8219.84Price / Book-5.713.345.325.76Net Income-$35.32M$29.98M$122.78M$993.25M7 Day Performance-3.67%-3.19%-0.19%3.26%1 Month Performance3.66%-2.53%3.73%5.21%1 Year Performance-35.25%-16.44%27.32%19.42% VolitionRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNRXVolitionRx1.5368 of 5 stars$0.63-2.2%$3.75+497.0%-34.2%$58.20M$1.29M-1.7480Analyst ForecastURGNUroGen Pharma4.0273 of 5 stars$10.04-2.0%$43.70+335.3%-34.1%$235.48M$89.36M-3.19200Analyst ForecastNews CoveragePositive NewsGap DownLFCRLifecore Biomedical1.5769 of 5 stars$6.35+1.0%$8.00+26.0%-1.4%$235.11M$130.86M79.38690Short Interest ↑ATAIAtai Life Sciences2.0165 of 5 stars$1.40-6.6%$9.00+542.4%-18.9%$235.09M$331,000.00-1.7380SOPHSOPHiA GENETICS2.9564 of 5 stars$3.54+22.5%$7.40+109.0%-32.0%$231.43M$64.49M-3.25520Short Interest ↓News CoveragePositive NewsELDNEledon Pharmaceuticals2.1913 of 5 stars$3.87-4.2%$16.00+313.4%+137.9%$231.19MN/A-1.9310Short Interest ↑News CoveragePositive NewsHRTXHeron Therapeutics3.9277 of 5 stars$1.52-1.9%$5.67+272.8%-25.9%$231.18M$137.74M-8.44300News CoveragePositive NewsCMPSCOMPASS Pathways3.026 of 5 stars$3.37-4.5%$33.60+897.0%-57.4%$230.58MN/A-1.53120Analyst ForecastNews CoverageGap UpDSGNDesign Therapeutics1.4653 of 5 stars$3.93-13.1%$7.00+78.1%+107.4%$222.52MN/A-4.6240Short Interest ↑LRMRLarimar Therapeutics1.3563 of 5 stars$3.48-4.9%$20.43+487.0%-20.7%$222.05MN/A-3.0330Gap UpFDMT4D Molecular Therapeutics3.4759 of 5 stars$4.79-13.2%$38.56+704.9%-74.2%$221.43M$17,000.00-1.68120Short Interest ↓Analyst RevisionNews Coverage Related Companies and Tools Related Companies URGN Alternatives LFCR Alternatives ATAI Alternatives SOPH Alternatives ELDN Alternatives HRTX Alternatives CMPS Alternatives DSGN Alternatives LRMR Alternatives FDMT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:VNRX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VNRX Stock Alerts